Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Recurrent Glioblasta Multiforme

Trial Name: A Randomized Phase I/II Study of ABT-888 In Combination With Temozolomide In Recurrent (Temozolomide Resistant) Glioblastoma

Protocol ID: RTOG 0929

Eligibility:

  • Histologically proven intracranial glioblastoma or gliosarcoma for the phase II component, any high-grade glioma is acceptable.  There must be imaging confirmation of tumor progression or regrowth.
  • Patients will be eligible if the original histology was lower grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made.
  • Age 18 and older
  • Must meet required laboratory values
  • Women of childbearing potential must have a negative pregnancy test prior to study enrollment.
  • Patient must be able to swallow oral medications

Ineligibility:

  • Prior invasive malignancy that is not the low-grade glioma, high-grade glioma, glioblastoma, or gliosarcoma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years.
  • Serious and inadequately controlled cardiac arrhythmia
  • Serious or non-healing wound, ulcer, or bone fracture
  • Pregnant or nursing women
  • Patient may not be on dialysis
  • History of chronic hepatitis B or C
  • Acquired immune deficiency syndrome (AIDS).  The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.

Anticipation of need for major surgical procedures during the course of the study

Enrollment: 240 patients

Benefits:

Taking part in this study may or may not make your health better.  While researchers hope that the combination of temozolomide and ABT-888 will be more useful against cancer compared to the usual treatment, there is no proof of this yet.  We do know that the information from this study will help researchers learn more about this drug combination as a treatment for cancer.  This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jan 18, 2013

Updated: Jan 18, 2013

« Return to Trials